Cover Image

Latency-reversing agents and cellular activation affect antigen processing in primary CD4 T cells

Saved in:

Bibliographic Details
Main Authors:	J. Boucau (Author), J. Madouasse (Author), D. Wambua (Author), M.J. Berberich (Author), S. Le Gall (Author)
Format:	Book
Published:	Elsevier, 2015-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Drug-induced modulation of cellular activation during latency reversal changes antigen processing and peptide presentation in primary CD4 T cells
by: J. Boucau, et al.
Published: (2017)

Memory CD4+ T cell subsets show differential responses to HIV latency-reversing agents
by: D.A. Kulpa, et al.
Published: (2015)

23 Understanding the effects of latency reversing agents on HIV RNA splicing: implications for latency reversal
by: T.M. Mota, et al.
Published: (2016)

The SMAC mimetic AZD5582 reverses HIV latency as a single agent in resting primary CD4+ T cells
by: G. Sampey, et al.
Published: (2019)

Approaches to discover latency-reversing agents
Published: (2015)

Optimisation of Smac mimetics as HIV-1 latency reversing agents
by: L. Pache, et al.
Published: (2019)

The contribution of memory CD4+ T cell subset phenotype to latency reversal efficiency
by: D.A. Kulpa, et al.
Published: (2017)

Lymphoid tissue and blood CD4 T cells respond differently to latency-reversing agents: are we testing the right cells?
by: A. Gramatica, et al.
Published: (2015)

Combinatorial latency reversal activity of inhibitor of apoptosis antagonists with mechanistically distinct classes of HIV latency reversal agents
by: Shane D. Falcinelli, et al.
Published: (2019)

OP 2.7 - 00057 The latency reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific CD8+ T-cells
by: D.C. Copertino, et al.
Published: (2022)

Co-culture of T-cells with dendritic cells facilitates HIV latency in proliferating CD4+ T-cells: implications for the establishment and reversal of latency
by: N. Kumar, et al.
Published: (2015)

Insights into mechanisms of HIV reactivation from latency using RNA-Seq gene expression profiling in CD4+ T cells and their maturation subsets following treatment with latency reversing agents.
by: N. Beliakova-Bethell, et al.
Published: (2017)

Histone deacetylase inhibitors induce transcription of unspliced but not multiply spliced HIV-1 RNA from proviral genomes during latency reversal, affecting antigen presentation and detection by CD8+ T cells
by: T. Mota, et al.
Published: (2019)

PP 5.4 - 00184 Optimization of Smac Mimetics as HIV-1 Latency Reversing Agents
by: L. Pache, et al.
Published: (2022)

OP 2.8 - 00193 Enhancing PKC Modulator HIV Latency Reversing Agents
by: M. Marsden, et al.
Published: (2022)

Identification of a promising new class of latency reversing agents
by: A. Gramatica, et al.
Published: (2017)

PP 1.3 - 00022 Signaling pathways that activate P-TEFb to reverse HIV latency in CD4+ T cells
by: U. Mbonye, et al.
Published: (2022)

Tissue-specific effects of latency-reversing agents on HIV transcriptional blocks in gut and blood
by: S. Telwatte, et al.
Published: (2019)

Maraviroc reactivates HIV with a potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells
by: S. Moreno, et al.
Published: (2019)

PP 1.22 - 00120 Suppression of CD4+ T-cell-intrinsic immunity by HIV-1 latency-reversing HDACi
by: J. Kazmierski, et al.
Published: (2022)

A theoretical framework to guide clinical trial design to estimate efficacies of latency-reversing agents
by: R. Ke, et al.
Published: (2015)

SMAC mimetics are potent latency reversal agents with single agent and combination activity ex vivo
by: R.M. Dunham, et al.
Published: (2017)

Novel use of alprazolam as a potential HIV-1 latency reversing agent
by: W. Elbezanti, et al.
Published: (2017)

Unprimed CD8 lymphocytes promote the establishment of HIV latency in CD4 T cells
by: L. Franchitti, et al.
Published: (2019)

PP 2.13 - 00160 Enhancing Tolerability and Efficacy of Latency Reversing Agents in "Kick and Kill" HIV Cure Approaches
by: J. Moran, et al.
Published: (2022)

HIV latency reversal using designed PKC modulators
by: M.D. Marsden, et al.
Published: (2017)

24 Thalidomide reverses latency of HIV-1 provirus
by: S. Samer, et al.
Published: (2016)

O3 Heme-arginate as a latency-reversing agent for HIV-1 cure
by: Michaela Madlenakova, et al.
Published: (2017)

Defining the Effects of PKC Modulator HIV Latency-Reversing Agents on Natural Killer Cells
by: Melanie Dimapasoc, et al.
Published: (2024)

26 A novel assay to evaluate the response of patient-derived virus to latency-reversing agents ex vivo
by: H. Lu, et al.
Published: (2016)

The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review
by: Quinten Debrabander, et al.
Published: (2023)

Differential effects of HIV latency-reversing agents on T cell phenotype and function: implications for HIV cure
by: G. Clutton, et al.
Published: (2015)

Reactivation capacity by latency reversing agents ex vivo correlates with the size of the HIV-1 reservoir
by: Gilles Darcis, et al.
Published: (2016)

OA4-4 Latency reversing agents induce HIV-1 protein expression in latently infected cells for cytotoxic T-lymphocyte antiviral recognition and killing
by: A. Ruiz, et al.
Published: (2016)

HIV-1 transcriptional latency in resting CD4 T-cell
by: M. Benkirane
Published: (2015)

OP 8.2 - 00033 Interleukin-2 administration is a potent latency reversal agent in people with treated HIV infection
by: M. Freeman, et al.
Published: (2022)

Sustained HIV release by single persisting CD4+ T cells during latency disruption
by: J.M. Hataye, et al.
Published: (2015)

Latency reactivating agents: impact on human macrophages physiology and susceptibility to HIV-1 infection
by: L. Hany, et al.
Published: (2019)

An unbiased platform to identify regulators of HIV latency in infected primary human CD4 T Cells
by: U. Rathore, et al.
Published: (2019)

PP 2.9 - 00125 Impact of latency reversal agents on estrogen receptor alpha gene and protein expression
by: C. Ceriani, et al.
Published: (2022)